ZICCUM AB submits patent application for thermostable dry-powder formulations of VLP-based vaccines (Virus-Like Particles)
10 July, 2020
Ziccum’s dry-powder formulation technology, LaminarPace, formulates vaccines that can meet, and surpass, WHO’s CTC (Cold Temperature Chain) requirements for vaccines, set at +40 degrees C. This unique formulation method could lead to a significant increase in the number of people globally who can be vaccinated.
"We are currently expanding our IP portfolio including the various virus types and compositions that are available and widely used for developing and manufacturing vaccines. By filing this patent application, we have further strengthened our IP position and laid the foundation for future industrial applications and collaborations," says CEO Göran Conradson. "We already have strong protection for LaminarPace technology, demonstrated by several approved patent that describe the basic drying method—but patent applications like this one add another dimension to the potential patent protection and exclusivity period a marketed dry-powder product can achieve."
For more information about Ziccum, please contact:
Göran Conradson: CEO Ziccum AB
Mob: +46 709 61 55 99
Ziccum AB (publ) develops new patented formulations of biological drugs where sensitivity to temperature differences, especially during transportation, currently limits medical and so commercial potential. The company’s patented technology, LaminarPace, develops dry powder formulations of drugs and vaccines that currently only exist in liquid form. By doing so Ziccum can increase the availability of drugs and vaccines in existing markets-and open up new ones.